We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer.
- Authors
Karayama, Masato; Inui, Naoki; Inoue, Yusuke; Yoshimura, Katsuhiro; Mori, Kazutaka; Hozumi, Hironao; Suzuki, Yuzo; Furuhashi, Kazuki; Fujisawa, Tomoyuki; Enomoto, Noriyuki; Nakamura, Yutaro; Asada, Kazuhiro; Uto, Tomohiro; Fujii, Masato; Matsui, Takashi; Matsuura, Shun; Hashimoto, Dai; Toyoshima, Mikio; Kusagaya, Hideki; Matsuda, Hiroyuki
- Abstract
Background: Lipids have immunomodulatory functions and the potential to affect cancer immunity. Methods: The associations of pretreatment serum cholesterol and long-chain fatty acids with the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated in 148 patients with non-small cell lung cancer who received nivolumab. Results: When each lipid was separately evaluated, increased low-density lipoprotein (LDL)-cholesterol (P < 0.001), high-density lipoprotein (HDL)-cholesterol (P = 0.014), total cholesterol (P = 0.007), lauric acid (P = 0.015), myristic acid (P = 0.022), myristoleic acid (P = 0.035), stearic acid (P = 0.028), linoleic acid (P = 0.005), arachidic acid (P = 0.027), eicosadienoic acid (P = 0.017), dihomo-γ-linolenic acid (P = 0.036), and behenic acid levels (P = 0.032) were associated with longer PFS independent of programmed death ligand 1 (PD-L1) expression. Meanwhile, increased LDL-cholesterol (P < 0.001), HDL-cholesterol (P = 0.009), total cholesterol (P = 0.036), linoleic acid (P = 0.014), and lignoceric acid levels (P = 0.028) were associated with longer OS independent of PD-L1 expression. When multiple lipids were evaluated simultaneously, LDL-cholesterol (P = 0.003), HDL-cholesterol (P = 0.036), and lauric acid (P = 0.036) were independently predictive of PFS, and LDL-cholesterol (P = 0.008) and HDL-cholesterol (P = 0.031) were predictive of OS. ORR was not associated with any serum lipid. Conclusions: Based on the association of prolonged survival in patients with increased serum cholesterol and long-chain fatty acid levels, serum lipid levels may be useful for predicting the efficacy of immune checkpoint inhibitor therapy.
- Subjects
BLOOD cholesterol; NON-small-cell lung carcinoma; BLOOD lipids; FATTY acids; EICOSANOIC acid
- Publication
Cancer Immunology, Immunotherapy, 2022, Vol 71, Issue 1, p203
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-021-02979-4